Key Findings:  The study shows the involvement of CB2 receptor agonism via WIN 55,212–2 inhibits renal cell carcinoma in vitro.
Type of Study:  Laboratory Study
Study Result:  Positive
Study Location(s):  Canada, Poland
Year of Pub:  2018
Cannabinoids Studied:  AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2